Considering the results of the present study together with these previous findings, we hypothesize that anti-HMGB1 monoclonal antibody therapy may be effective in treating GBS generally, while sRAGE may be a promising target for treating the AMAN subtype specifically. This evidence concerns the gene HMGB1 and Guillain-Barre syndrome.